SUBSCRIBE
SUBSCRIBE
Biotech Bay

Genelabs Technologies, Inc. Announces Presentation Of Data On Non-Nucleoside HCV Polymerase Inhibitor at the 15th International Symposium on Hepatitis C Virus and Related Viruses

October 9, 2008 | 
1 min read
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Genelabs Technologies, Inc. (Nasdaq:GNLB) announced that three presentations were made at the 15th International Symposium on Hepatitis C Virus and Related Viruses, each on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.
Events
MORE ON THIS TOPIC
Social media networking. Network with members connected with each other. Group of people. Communication, teamwork, community, society. Abstract concept with wooden pieces on blue background.
FDA
Moderna’s Outright Flu Refusal Just the Latest Case of Crossed FDA Signals
February 13, 2026
 · 
6 min read
 · 
Heather McKenzie
Viral vector, gene therapy, DNA delivery. Virus inserting genetic material into a cell nucleus. Gene editing, therapeutic genes, engineering, genetic diseases, dna, CRISPR, biotechnology. Medicine 3D illustration
Gene therapy
In Vivo Is Having a Moment as Cell and Gene Therapy Sector Gathers in San Diego
February 11, 2026
 · 
4 min read
 · 
Heather McKenzie
Sunset skyline of San Diego downtown viewed from Coronado Island.
gene therapy
Advanced Therapies Week 2026: ‘Solving for Science’ and Weathering Global Complexity
January 28, 2026
 · 
4 min read
 · 
Heather McKenzie
Organizing Solutions and organizer concept as a Management leadership taking charge as a leader sorting out diverse ropes into an organized patterns as a business concept for strategy and control.
FDA
JPM26: Beam, Cabaletta, More Zero In on Regulatory Alignment After Tumultuous Year
January 19, 2026
 · 
6 min read
 · 
Heather McKenzie